Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. ACN
5. IBM
6. SPY
7. NVDA
8. PRIM
9. PFE
10. TSLA

Go back to Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors
AGIOS PHARM (NASDAQ: AGIO) Delayed: 35.67 +0.57 (1.62%)
Previous Close $35.10    52 Week High $71.49 
Open $34.82    52 Week Low $33.50 
Day High $35.74    P/E N/A 
Day Low $34.63    EPS $-1.18 
Volume 320,216